Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28016001 | 1.00 | CA1 (0.47) | CA1CA2MEN1KMT2APABPC1 | |
| SCHEMBL30269658 | 1.00 | CA1 (0.47) | CA1CA2MEN1KMT2APABPC1 | |
| SCHEMBL1688213 | 0.82 | KCNH2 (0.56) | CA1CA2MEN1KMT2APABPC1 | |
| SCHEMBL28819367 | 0.81 | CA1 (0.61) | CA1CA2MEN1KMT2APABPC1 | |
| SCHEMBL2120289 | 0.81 | KDM4E (0.53) | CA1CA2MEN1KMT2APABPC1 | |
| SCHEMBL3511652 | 0.81 | CA1 (0.47) | CA1CA2MEN1KMT2APABPC1 | |
| SCHEMBL1422284 | 0.81 | CA1 (0.61) | CA1CA2MEN1KMT2APABPC1 | |
| SCHEMBL307288 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KDM4EMAPTHSD17B10TDP1 | |
| SCHEMBL29995133 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KDM4EMAPTHSD17B10TDP1 | |
| SCHEMBL24010110 | 0.79 | KCNH2 (0.47) | CA1CA2MEN1KMT2APABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-20260014119-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-08-19 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| EP-3728194-B1 | QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | OTAGO INNOVATION LTD (NZ) | 2025-06-04 | — | — | EP | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119731160-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1597256-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050187246-A1 | Cell proliferation inhibitors | LI QUN (US) | 2005-08-25 | — | — | US | disclosed |
| US-6924304-B2 | Cell proliferation inhibitors | ABBOTT LABORATORIES (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004074283-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | disclosed |
| US-6521658-B1 | Cell proliferation inhibitors | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014119-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBP, EBPL, ELP1 | CA1 4231/4885CA2 3616/4885MEN1 4509/4885 |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | JAK2, STAT3, STAT5A | CA1 1768/4885CA2 573/4885MEN1 319/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | CA1 1778/4885CA2 199/4885MEN1 866/4885 |
| US-20030096856-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNA1 | CA1 2753/4885CA2 3385/4885MEN1 757/4885 |
| US-20050187246-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNC | CA1 3410/4885CA2 3387/4885MEN1 1314/4885 |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ADORA1, ADORA2A | CA1 228/4885CA2 224/4885MEN1 1556/4885 |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | CA1 740/4885CA2 1669/4885MEN1 2219/4885 |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | CCNI, MKI67, TK1 | CA1 2916/4885CA2 739/4885MEN1 2174/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | CA1 881/4885CA2 256/4885MEN1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.